Bovine Respiratory Disease Treatment Market - Forecast(2024 - 2030)

Bovine Respiratory Disease Treatment Market size is estimated to reach $1.3 billion by 2027, growing at a CAGR of 9.3% during the forecast period 2022-2027. Bovine respiratory disease (BRD) is the most typical and expensive ailment affecting beef cattle in the world. It is a complicated, bacterial infection that brings about pneumonia in calves which can be deadly. The infection is customarily a total of three co-reliant determinants: stress, an underlying viral infection, and a novel bacterial infection. Bovine respiratory disease (BRD) is one of the most typical indications for antimicrobial therapy in beef cattle production and research trials display that antibiotic therapy considerably enhances clinical outcomes for BRD. The therapeutic approach for bovine respiratory disease (BRD) involves antimicrobial treatment owing to the repeated association of bacteria. The data regarding the application of ancillary drugs (like anti-inflammatory drugs or immunomodulators) are meager and frequently are based on experimental models of BRD. Treatment should always be particularly aimed at the ailment and the symptoms (anti-infectious agents(Antibiotics and Sulfas), antiparasiticides, non-steroidal anti-inflammatories, bronchodilators, mucolytics, oral rehydration fluids) in consultation with the accompanying veterinarian. Treatment of BRD can involve the suggestion to utilize third generation cephalosporins, fluoroquinolones, florfenicol (a relative of chloramphenicol), or tilmicosin, a macrolide antibiotic.

The proliferating intake of beef and the expanding population is set to drive the Bovine Respiratory Disease Treatment Market. The rising rate of infections caused by bacteria, viruses, and parasites globally influencing the immune system of calves and the increasing predominance of bovine respiratory disease requiring treatment through the application of third-generation cephalosporins are set to propel the growth of the Bovine Respiratory Disease Treatment Market during the forecast period 2022-2027. This represents the Bovine Respiratory Disease Treatment Industry Outlook.

Report Coverage

The report: “Bovine Respiratory Disease Treatment Market Forecast (2022-2027)”, by Industry ARC, covers an in-depth analysis of the following segments of the Bovine Respiratory Disease Treatment Market.

By Treatment Type: Vaccines, Antibiotics, NSAIDs, Immunomodulators, Others.
By Disease Type: Lower Respiratory Tract Infections, Upper Respiratory Tract Infections, Diphtheria.
By Distribution Channel: Veterinary Hospitals, Veterinary Clinics, Private Veterinary Pharmacies, Veterinary Research Institutes.
By Geography: North America (U.S, Canada and Mexico), Europe (Germany, France, UK, Italy, Spain, Russia and Rest of Europe), Asia-Pacific (China, Japan, South Korea, India, Australia & New Zealand, and Rest of Asia-Pacific), South America (Brazil, Argentina, Chile, Colombia, Rest of South America), and Rest Of The World (Middle East, Africa).

Key Takeaways

• Geographically, North America Bovine Respiratory Disease Treatment Market accounted for the highest revenue share in 2021 and it is poised to dominate the market over the period 2022-2027 owing to the increasing domestic generation, intake, and export of bovine meat and the increasing pervasiveness of bovine respiratory disease requiring application of third-generation cephalosporins in the North American region.
• Bovine Respiratory Disease Treatment Market growth is being driven by the increasing pervasiveness of numerous causative agents for respiratory ailments amidst bovines and expeditiously altering environmental determinants. However, there are some complications that are related to the diagnosis of the bovine respiratory disease which requires the application of third-generation cephalosporins for treatment, and the presumptive diagnosis subsequent to a physical examination is hard owing to the similarities of clinical signs and modification of likely bacteria thereby making the diagnostic process complex which is one of the major factors hampering the growth of Bovine Respiratory Disease Treatment Market. 
• Bovine Respiratory Disease Treatment Market Detailed Analysis on the Strength, Weakness, and Opportunities of the prominent players operating in the market will be provided in the Bovine Respiratory Disease Treatment Market report. 

 Bovine Respiratory Disease Treatment Market: Market Share (%) by Region, 2021

For More Details on This Report - Request for Sample

Bovine Respiratory Disease Treatment Market Segment Analysis – By Treatment Type

The Bovine Respiratory Disease Treatment Market based on treatment type can be further segmented into Vaccines, Antibiotics, NSAIDs, Immunomodulators, and Others. The Vaccines segment held the largest market share in 2021. This growth is owing to the soaring accessibility of a huge series of bovine vaccines for dairy and beef cattle to safeguard them against severe respiratory ailments like a bovine respiratory disease. Cephalosporins are also utilized in the treatment of bovine respiratory disease. The surging count of novel vaccine launches by different firms is further propelling the growth of the Vaccine segment.

Furthermore, the Antibiotics segment is estimated to grow with the fastest CAGR of 10.4% during the forecast period 2022-2027 owing to the surging application of antibiotics and anti-inflammatory medications being utilized for combination treatment which is anticipated to enhance the success rate of the treatment.

Bovine Respiratory Disease Treatment Market Segment Analysis – By Distribution Channel

The Bovine Respiratory Disease Treatment Market based on distribution channel can be further segmented into Veterinary Hospitals, Veterinary Clinics, Private Veterinary Pharmacies, and Veterinary Research Institutes. The Veterinary Hospitals Segment held the largest market share in 2021. This growth is owing to the increasing predominance of bovine respiratory disease among cattle resulting in the establishment of a greater count of veterinary hospitals for the treatment of affected cattle. Cephalosporins are applied in the treatment of bovine respiratory disease. The proliferating count of treatment procedures is further propelling the growth of this segment.

Furthermore, the Veterinary Research Institutes segment is estimated to grow with the fastest CAGR of 10.8% during the forecast period 2022-2027 owing to the soaring research activities focused on bovine respiratory disease including the Veterinary Medicine Teaching and Research Center at the University of California -Davis apart from the application of cephalosporins in the treatment of bovine respiratory disease.

Bovine Respiratory Disease Treatment Market Segment Analysis – By Geography

The Bovine Respiratory Disease Treatment Market based on geography can be further segmented into North America, Europe, Asia-Pacific, South America, and Rest of the World. North America (Bovine Respiratory Disease Treatment Market) held the largest share with 35% of the overall market in 2021. The growth of this region is owing to the increasing predominance of bovine respiratory disease in cattle in the North American region. Cephalosporins are utilized for the treatment of bovine respiratory disease. The surging in-house generation and surplus intake of bovine meat is further propelling the growth of the Bovine Respiratory Disease Treatment Market in the North American region.

Furthermore, the Asia-Pacific region is estimated to be the region with the fastest CAGR rate over the forecast period 2022-2027. This growth is owing to factors like the enormous livestock animal pool and the increasing pervasiveness of bovine respiratory disease requiring the application of cephalosporins in the Asia-Pacific region. The soaring awareness of animal health and the launch of government initiatives toward the treatment of bovine respiratory disease is further fuelling the progress of the Bovine Respiratory Disease Treatment Market in the Asia-Pacific region.

Bovine Respiratory Disease Treatment Market - Drivers

Surging Applications Of Cephalosporins Are Projected To Drive The Growth Of Bovine Respiratory Disease Treatment Market:

Cephalosporin medications are efficient treatments for numerous typical cattle ailments. These beneficial medicines are efficient, readily accessible, cost-efficient, and possess short milk and meat withholding times. Ceftiofur and cephapirin are the only cephalosporins authorized for application in the U.S. There are authorized applications of injectable ceftiofur in cattle. The medication Excede Sterile Suspension (Ceftiofur Crystalline Free Acid) targeted for cattle (other than ruminating) is designated for application in the treatment of bovine respiratory disease (shipping fever, pneumonia) and Food rot. The labeled dose includes 1.5 mL/100 lbs once. The Route of Administration involves subcutaneous injection at the base of the ear (BOE). The values for Meat W/D and Milk W/D are 13 days and 0 hrs respectively. Cefquinome is a fourth-generation cephalosporin with pharmacological and antibacterial characteristics priceless in the treatment of coliform mastitis and additional infections. It is only utilized in veterinary uses. Cefquinome sulfate Injections are utilized by the intramammary route in lactating cows for efficient milking. Cefquinome sulfate is also utilized in the treatment of bovine respiratory disease (BRD) related to Mannheimia haemolytica, Pasteurella multocida and Histophilus somni sensitive to cefquinome. The surging applications of cephalosporins are therefore fuelling the growth of the Bovine Respiratory Disease Treatment Market during the forecast period 2022-2027.

Proliferating Applications Of Combinations Of Antibiotics And Anti-Inflammatory Agents Are Expected To Boost The Demand For Bovine Respiratory Disease Treatment:

The therapeutic approach to bovine respiratory disease (BRD) frequently includes a combination of an antibiotic with an anti-inflammatory agent. Investigations have been performed to assess the clinical impact of a novel combination product including tulathromycin and ketoprofen for the treatment of naturally happening BRD. The tulathromycin-ketoprofen and tulathromycin treatment class displayed a treatment success rate of 94.2% and 95.0%, respectively, and a relapse rate of 3.8% and 4.0%, respectively. Tulathromycin-ketoprofen displayed better pyrexia control in comparison with tulathromycin within the first 24 h succeeding treatment. Tulathromycin-ketoprofen-treated animals displayed quicker enhancement of their clinical symptoms (respiration and depression score). It can be concluded from these investigations that the efficiency of tulathromycin-ketoprofen for the treatment of BRD was non-inferior to tulathromycin. The combination product clearly presented more pronounced fever regulation than tulathromycin which is acknowledged as advantageous for animal welfare. The proliferating applications of antibiotics are therefore driving the growth of the Bovine Respiratory Disease Treatment Market during the forecast period 2022-2027.

Bovine Respiratory Disease Treatment Market Challenges

Challenges Of Bovine Respiratory Disease (BRD) Are Hampering The Growth Of The Bovine Respiratory Disease Treatment Market:

Bovine respiratory disease (BRD) is the most typical and expensive ailment of beef cattle in North America. Bovine respiratory diseases (BRD) and undifferentiated fevers are estimated to cost the North American cattle industry up to US$1 billion every year. In spite of comprehensive research, industry practices are frequently more informed by belief than by fact. Repeatedly backed interventions, inclusive of vaccination, different processing processes, and nutritional manipulation, have a restricted effect on morbidity and mortality. Proof for application of oral antimicrobials, either in feed or water, seems to be uncertain. In contrast, preconditioning and metaphylaxis have considerable scientific proof of efficiency, with weaning before sale conceivably being the most significant constituent of preconditioning. The inability to attain more definitive conclusions in avoiding BRD may be attributable to hardships in inspecting the ailment. Investigation challenges include the possibility of extensive confounding, tremendous variability, the multi-factorial nature of the ailment, and insufficient techniques for diagnosis. These issues are thus hampering the growth of the Bovine Respiratory Disease Treatment Market.

Bovine Respiratory Disease Treatment Industry Outlook:

Product and treatment launches, mergers and acquisitions, geographic expansions, and R&D activities are key strategies adopted by players in the Bovine Respiratory Disease Treatment Market. Key companies in this market are:

1. Bayer Corporation
2. Boehringer Ingelheim GmbH
3. Bimeda Animal Health
4. Elanco Animal Health
5. Vetoquinol S.A.
6. Merck & Co Inc.
7. Zoetis Inc.
8. Novartis Animal Health
9. Vibrac S.A.
10. Ceva Animal Health

Recent Developments

• In August 2021, Zoetis declared a novel combination product to treat bovine respiratory disease (BRD) and regulate associated fever (pyrexia): Draxxin® KP (tulathromycin and ketoprofen injection) Injectable Solution. It is a novel single-treatment alternative for beef and dairy producers. Draxxin KP involves the well-recognized efficiency of Draxxin® (tulathromycin injection) Injectable Solution and includes ketoprofen, a fast-acting nonsteroidal anti-inflammatory drug (NSAID), in a single treatment certified for application in beef steers, beef heifers, beef calves two months of age and older, beef bulls, dairy bulls, and dairy replacement heifers.
• In December 2020, Ceva Animal Health introduced Tulaven 100mg/ml (tulathromycin) for bovine respiratory disease (BRD). Tulaven is authorized for the treatment and metaphylaxis of BRD related to Mannheimia haemolytica, Pasteurella multocida, Histophilus somni and Mycoplasma bovis. Tulaven can also be utilized to treat Infectious Bovine Keratoconjunctivitis (IBK) related to Moraxella bovis and Porcine Respiratory Disease Complex (PRDC) related to Actinobacillus pleuropneumoniae, Pasteurella multocida, Mycoplasma hyopneumoniae, Haemophilus parasuis and Bordetella bronchiseptica.
• In December 2020, Bimeda UK declared the introduction of Macrosyn solution for injection for cattle, pigs, and sheep [POM-V], which includes 100mg/ml tulathromycin. Succeeding suitable diagnostics, Macrosyn solution for injection for cattle, pigs, and sheep is designated for application to treat particular conditions brought about by particular bacteria vulnerable to tulathromycin. In cattle, it is applied for the treatment of bovine respiratory disease (BRD) (M. haemolytica, P. multocida, H. somni, M. bovis) and infectious bovine keratoconjunctivitis (IBK) (Moraxella bovis),

Related Reports

Veterinary Vaccines Market – Forecast (2022 - 2027)

Report Code: HCR 0058

Respiratory Infectious Disease Diagnostics Market - Forecast 2021 - 2026

Report Code: HCR 72918

Veterinary Software Market – Forecast (2022 - 2027)

Report Code: HCR 0438

 For more Lifesciences and Healthcare Market reports, please click here